MedTrace Logo

PCSK 9 Inhibition as Secondary Prevention in Renal Transplant Patients

NCT04665830 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2020-12-14

No results posted yet for this study

Summary

From this randomized controlled study, we aim to:

A.Do do cardiovascular risk stratification of renal transplant recipients who are followed up in Hamed Al-Essa organ transplant center of Kuwait.

B. To compare the effectiveness of a PCSK9 inhibitor plus maximum tolerated statin therapy vs. maximum tolerated statin therapy alone in the reduction of major cardiovascular events among renal transplant recipients with cardiovascular disease.

C. To compare the effectiveness of a PCSK9 inhibitor plus maximum tolerated statin therapy vs. maximum tolerated statin therapy alone in terms of LDL-C-lowering, muscle symptoms, and quality of life.

D. To compare patient adherence to the different treatment protocols.

Conditions

  • Kideny Transplant Recipients With High Cardiovascular Risk Score

Interventions

DRUG

Evolocumab

treated patients with evolocumab for high cholesterol

Sponsors & Collaborators

  • Hamid Al-Essa Organ Transplant Center

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-01
Primary Completion
2020-05-01
Completion
2020-05-01

Countries

  • Kuwait

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04665830 on ClinicalTrials.gov